AI Article Synopsis
- Epstein-Barr virus (EBV) can lead to lymphoproliferative disorders, especially in people with weakened immune systems, due to T-cell dysfunction and inability to control the virus.
- Antiviral treatments exist with low toxicity, but traditional drugs like aciclovir and ganciclovir are less effective for EBV-related issues since they rely on a specific viral enzyme that is often missing in these cases.
- The drug arginine butyrate can activate the necessary enzyme in lymphoma cells when combined with ganciclovir, while foscarnet works effectively against the virus's DNA, providing successful treatment and complete remissions in affected patients.
Article Abstract
Epstein-Barr virus (EBV)-associated lymphoproliferations may arise in individuals with hereditary or acquired immunodeficiencies. T-cell dysfunction and resulting insufficient control of EBV infection is common to all these patients in whom EBV-associated lymphoproliferations develop. EBV is an oncogenic virus which induces proliferation and transformation of B-lymphocytes. Antiviral treatment may represent a causal treatment option with relatively low toxicity. Among the different antiviral drugs aciclovir and ganciclovir are not the drugs of choice, because in EBV-associated lymphoproliferations the viral thymidine kinase enzyme is not encoded regularly. The agent arginine butyrate has the ability to selectively activate EBV thymidine kinase genes in EBV-infected lymphoma cells. In combination with ganciclovir it has demonstrated efficacy in patients with EBV-associated lymphoproliferations after solid organ transplantation. The action of foscarnet, another antiviral agent, is directed against the viral DNA, independent of the presence of the viral thymidine kinase. In our experience treatment with foscarnet resulted in continuous complete remissions in patients with EBV-associated lymphoproliferations. These clinical experiences demonstrate the efficacy of antiviral treatment in EBV-associated lymphoproliferations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-3-642-56352-2_11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EBV and post-transplant lymphoproliferative disorder: a complex relationship.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Pediatrics, Division of Hematology and Oncology, Baylor College of Medicine, Houston, TX.
Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous category of disease entities occurring in the context of iatrogenic immune suppression. Epstein-Barr virus (EBV)-driven B-cell lymphoproliferation represents the prototype of quintessential PTLD, which includes a range of histologies named nondestructive, polymorphic, and monomorphic EBV+ diffuse large B-cell lymphoma (DLBCL) PTLD. While EBV is associated with the majority of PTLD cases, other drivers of lymphoid neoplasia and lymphoma transformation can occur-with or without EBV as a codriver-thus underlining its vast heterogeneity.
View Article and Find Full Text PDFRapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Article Synopsis
- Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
- Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
- Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
Clinicopathologic Insights and Molecular Oncogenesis: Understanding Epstein-Barr Virus-Induced B-cell Lymphoproliferations.
Int J Surg Pathol
August 2024
Department of Pathology and Clinical Laboratories, Michigan Medicine, Ann Arbor, MI, USA.
Article Synopsis
- Epstein-Barr virus (EBV) is common among adults and usually remains dormant without causing problems in healthy individuals.
- However, in those with weakened immune systems, EBV can lead to serious health issues like autoimmune disorders and various types of cancers, particularly certain lymphomas.
- The text examines how EBV contributes to these diseases, detailing their mechanisms, characteristics, and clinical features.
Enhancing diagnostic precision in EBV-related HLH: a multifaceted approach using F-FDG PET/CT and nomogram integration.
Cancer Imaging
August 2024
Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China.
Article Synopsis
- Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) complicates lymphoma detection using F-FDG PET/CT, prompting researchers to enhance diagnostic methods by integrating laboratory parameters.
- A study involving 46 patients identified a nomogram that combined key factors (SUVmax ratio, plasma EBV-DNA copies, and IFN-γ) achieving 100% sensitivity and 81.8% specificity for diagnosis, as well as prognostic insights for mortality risk.
- The findings suggest that while F-FDG PET/CT alone has diagnostic limitations in active EBV cases, using the nomogram greatly improves accuracy and correlates with patient prognosis.
Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge.
Expert Rev Clin Immunol
November 2024
Department of Pediatrics, Allergy Immunology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Introduction: Inborn errors of immunity (IEI) are a group of genetically heterogeneous disorders with a wide-ranging clinical phenotype, varying from increased predisposition to infections to dysregulation of the immune system, including autoimmune phenomena, autoinflammatory disorders, lymphoproliferation, and malignancy. Lymphoproliferative disorder (LPD) in IEI refers to the nodal or extra-nodal and persistent or recurrent clonal or non-clonal proliferation of lymphoid cells in the clinical context of an inherited immunodeficiency or immune dysregulation. The Epstein-Barr virus (EBV) plays a significant role in the etiopathogenesis of LPD in IEIs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!